
BENZONATATE- benzonatate capsule Proficient Rx LP Reference Label Set Id: 7a82fe3b-1bc8-4092-bebc-dad00063835b Reference Label Set Id: 1d46d582-3bfe-44f6-9b63-f827b957b409 Reference Label Set Id: 1310a1c3-601e-468b-b573-69562141ce0d

DESCRIPTION

Benzonatate, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.7.



Each soft gelatin capsule, for oral administration, contains 100 mg or 200 mg of benzonatate USP. Benzonatate Capsules, USP also contain the following inactive ingredients: D&C Yellow # 10, gelatin, glycerin, purified water, methylparaben, propylparaben and titanium dioxide.

CLINICAL PHARMACOLOGY

Benzonatate acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate has no inhibitory effect on the respiratory center in recommended dosage.

INDICATIONS AND USAGE

Benzonatate is indicated for the symptomatic relief of cough.

CONTRAINDICATIONS

Hypersensitivity to benzonatate or related compounds.

WARNINGS

Hypersensitivity

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and

supportive measures.

Psychiatric Efects

Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking benzonatate in combination with other prescribed drugs.

Accidental Ingestion and Death in Children

Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see **OVERDOSAGE**).

PRECAUTIONS

Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Information for Patients Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush Benzonatate Capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of foods or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.

Keep benzonatate out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately. Overdosage resulting in death may occur in adults. Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of benzonatate capsule, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate at one time.

Usage in Pregnancy

PREGNANCY CATEGORY C

Animal reproduction studies have not been conducted with benzonatate. It is also not known whether benzonatate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate should be given to a pregnant woman only if clearly needed.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate is administered to a nursing woman.

Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenicity, mutagenicity, and reproduction studies have not been conducted with benzonatate.

Pediatric Use

Safety and effectiveness in children below the age of 10 have not been established. Accidental ingestion resulting in death has been reported in children below age 10. Keep out of reach of children.

ADVERSE REACTIONS

Potential Adverse Reactions to benzonatate may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

CNS: sedation; headache; dizziness; mental confusion; visual hallucinations.

GI: constipation; nausea; GI upset.

Dermatologic: pruritus; skin eruptions.

Other: nasal congestion; sensation of burning in the eyes; vague "chilly" sensation; numbness of the chest; hypersensitivity. Deliberate or accidental overdose has resulted in death, particularly in children.

OVERDOSAGE

Intentional and unintentional overdose may result in death, particularly in children. The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

Signs and Symptoms

The signs and symptoms of overdose of benzonatate have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise. CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.

Treatment:

In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage. Do not use CNS stimulants.

DOSAGE AND ADMINISTRATION

Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. **Benzonatate should be swallowed whole.** Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed.

HOW SUPPLIED

Benzonatate Capsules USP, 100 mg: Yellow soft gelatin capsules, imprinted "ASC" on one side and "105" on the other side, available in bottles of 10s (NDC 63187-016-10), 15's (63187-016-15), 20's (63187-016-20) 30's (NDC 63187-016-30) and 40's (63187-016-40).

Benzonatate Capsules USP, 200 mg: Yellow soft gelatin capsules, imprinted "ASC" on one side and "106" on the other side, available in bottles of 10s (NDC 63187-185-10), 14s (63187-185-14), 20's (63187-185-20), 21's (63187-185-21) 30's (NDC 63187-185-30) 40 (63187-185-40) and 60's (63187-185-60).


Store at controlled room temperature 20° - 25°C (68° - 77°F) [See USP].

Manufactured by Intergel Division of IVC Industries, Inc. Irvington, NJ 07111

Manufactured for Ascend Laboratories, LLC Montvale, NJ 07645 Rev 12/11

Repackaged by: **Proficient Rx LP Thous and Oaks, CA 91320**

Principal Display Panel



	Proficient	NDC 63187-185-21	Lot #:000 Exp. 00/ RX# M/	
Benzo	onatate 200m	RX Only	Benzonatate 200mg #21 Capsules Lot #:00000 NDC 63187-185-21	Rx# MASTER Exp:00/00/00
#21	Capsules	ains: Benzonatate, USP	Benzonatate 200mg #21 Capsules Lot #:00000 NDC 63187-185-21	Rx# MASTER Exp:00/00/00
200mg Yellow soft gel	atin capsules, imprinted "106"		Benzonatate 200mg #21 Capsules Lot #.00000 NDC 63187-185-21	Rx# MASTER Exp:00/00/00
	D: PB018521 Division of IVC Industries, Inc. Irvington, °C (68°-77°F)	NJ 07111 Keep medication out of the reach of children	Packaged By: Prof Thousand Oaks, C	

BENZONATATE

Product Informat	tion							
Product Type		HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:63					187-016(N	DC:67877-105
Route of Administra	tion	n ORAL						
Active Ingredient	t/Active M	oiety						
Ingredient Name						Basis of Strengt		Strength
benzonatate (UNII: 5P4	4DHS6ENR)(benzonatate - UNII	:5P4DHS6ENR)		benzor	1a ta te		100 mg
Inactive Ingredie	nts							
		Ingredien	t Name				St	trength
D&C YELLOW NO. 10) (UNII: 35SW	5USQ3G)						
GELATIN, UNSPECIFI	ED (UNII: 2G8	36QN327L)						
glycerin (UNII: PDC6A	3C0OX)							
water (UNII: 059QF0K0	00R)							
methylparaben (UNII:	A218C7HI9T)							
propylparaben (UNII:	Z8IX2SC1OH)						
		,						
titanium dioxide (UNI	I: 15FIX9V2JF							
Product Characte	eristics	'))						
Product Characte	e ristics	") w	Score				no score	
Product Characte Color Shape	eristics	") w	Size				19 m m	
Product Characte Color Shape Flavor	e ristics	") w		ode				
Product Characte Color Shape	e ristics	") w	Size	ode			19 m m	
Product Characte Color Shape Flavor Contains	e ristics	") w	Size	ode			19 m m	
Product Characte Color Shape Flavor Contains Packaging	e ristics	") w	Size Imprint Co	ode Market	ing Sta		19mm ASC;105	ing End Dat
Product Characte Color Shape Flavor Contains Packaging # Item Code	e ristics yello CAPS	w SULE Package Desc	Size Imprint Co	Market	-		19mm ASC;105	ing End Dat
Product Characte Color Shape Flavor Contains Packaging # Item Code 1 NDC:63187-016-10	Pristics yello CAPS	w SULE Package Desc FLE; Type 0: Not a	Size Imprint Co	Market	17		19mm ASC;105	ing End Dat
Product Characte Color Shape Flavor Contains Product Characte Image: Shape Image: Sh	Pristics yello CAPS CAPS 10 in 1 BOTT 15 in 1 BOTT 20 in 1 BOTT	y) w SULE SULE TLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a	cription Combination Produ Combination Produ	Market act 09/01/201 ct 04/01/201 act 04/01/201	17 14 14		19mm ASC;105	ing End Dat
Product Characte Color Shape Flavor Contains Packaging MC:63187-016-10 NDC:63187-016-15 NDC:63187-016-20	Pristics yello CAPS CAPS CAPS CAPS CAPS CAPS CAPS CAPS	W SULE FLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a	Size Imprint Co Sombination Produ Combination Produ Combination Produ	Market act 09/01/201 ct 04/01/201 act 04/01/201 act 04/01/201	17 14 14		19mm ASC;105	ing End Dat
Product Characte Color Shape Flavor Contains Perspective Perspective Item Code NDC:63187-016-10 NDC:63187-016-20 NDC:63187-016-20 NDC:63187-016-20 NDC:63187-016-30	Pristics yello CAPS CAPS CAPS CAPS CAPS CAPS CAPS CAPS	W SULE FLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a TLE; Type 0: Not a	cription Combination Produ Combination Produ	Market act 09/01/201 ct 04/01/201 act 04/01/201 act 04/01/201	17 14 14 15		19mm ASC;105	ing End Dat
Product Characte Color Shape Flavor Contains Perspective MC:63187-016-10 NDC:63187-016-10 NDC:63187-016-20 NDC:63187-016-30 NDC:63187-016-30 NDC:63187-016-30 NDC:63187-016-30	eristics yello CAPS CAPS CAPS CAPS CAPS CAPS CAPS CAPS	w SULE FLE; Type 0: Not a FLE; Type 0: Not a	Size Imprint Co Sombination Produ Combination Produ Combination Produ	Market act 09/01/201 ct 04/01/201 act 04/01/201 act 04/01/201	17 14 14 15		19mm ASC;105	ing End Dat
S → p e F → v r C → rtains B → v c	eristics yellov CAPS CAPS CAPS CAPS CAPS CAPS CAPS CAPS	w SULE Package Desc FLE; Type 0: Not a FLE; Type 0: Not a FLE; Type 0: Not a FLE; Type 0: Not a FLE; Type 0: Not a	Size Imprint Co Sombination Produ Combination Produ Combination Produ	Market act 09/01/201 act 04/01/201 act 04/01/201 act 04/01/201 act 11/01/201	17 14 14 15 6		19 mm ASC;105 Market	ing End Date

BENZONATATE

benzonatate capsule

Product T ype	HUMAN PRESCRIPTION DRUG Iter			Item Cou	le (Source	NDC:63	3187-185(N	DC:67877-106	
) 1120.00	107 105(11	DG.07077 100			
Route of Administra	tion	ORAL							
Active Ingredien	t/Active	Moiety							
Ingredient Name					Basis of Strength			Strength	
benzonatate (UNII: 5P	HS6ENR)		benz	o na ta te		200 mg			
Inactive Ingredie	nts								
Ingredient Name							Strength		
D&C YELLOW NO. 1	0 (UNII: 355	•						-	
GELATIN, UNSPECIF	IED (UNII: 2	2G86QN327L)							
glycerin (UNII: PDC6A	3C0OX)								
water (UNII: 059QF0K	00R)								
methylparaben (UNII:		· ·							
propylparaben (UNII:		,							
titanium dioxide (UN	II: 15FIX9V2	2JP)							
Product Characte	eristics								
		LLOW	Score				no score		
Color	YE	LLO W PSULE	Score Size				no score 19mm		
Product Characte Color Shape Flavor	YE			ode					
Color Shape	YE		Size	ode			19 mm		
Color Shape Flavor	YE		Size	ode			19 mm		
Color Shape Flavor Contains	YE		Size	ode			19 mm		
Color Shape Flavor Contains Packaging	YE	PSULE	Size Imprint C		arketing S	tart Date	19 mm ASC;106	ting End Dat	
Color Shape Flavor Contains Packaging # Item Code			Size Imprint C	М	arketing S /0 1/20 17	tart Date	19 mm ASC;106	ting End Dat	
Color Shape Flavor Contains Contains Contains Contains	YE CA 10 in 1 BC	PSULE Package Descripti	Size Imprint C on pination Prod	M luct 09	0	tart Date	19 mm ASC;106	ting End Dat	
Color Shape Flavor Contains C	YE CA 10 in 1 BC 14 in 1 BO	PSULE Package Descripti TTLE; Type 0: Not a Comb	Size Imprint C ion bination Prod	M luct 09 uct 06	/0 1/20 17	tart Date	19 mm ASC;106	ting End Dat	
Color Shape Shape Kerner Kerne	YE CA 10 in 1 BC 14 in 1 BC 20 in 1 BC	PSULE Package Descripti PTTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb	Size Imprint C on bination Prod bination Prod	M luct 09 luct 06 luct 07	/0 1/20 17 /20 /20 17	tart Date	19 mm ASC;106	ting End Dat	
S → p e S → a p e F → a readed with the second withe second withe second with the second withe second with	YE CA 10 in 1 BC 14 in 1 BC 20 in 1 BC 21 in 1 BC	PSULE Package Descripti TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb DTTLE; Type 0: Not a Comb	Size Imprint C ion pination Prod pination Prod pination Prod	M luct 09 luct 06 luct 07/ uct 06	/0 1/20 17 /20 /20 17 /0 1/20 14	tart Date	19 mm ASC;106	ting End Dat	
Image: Simple stress in the stress in th	YE CA 10 in 1 BC 14 in 1 BC 20 in 1 BC 30 in 1 BC	PSULE Package Descripti TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb	Size Imprint C on bination Prod bination Prod bination Prod bination Prod bination Prod	M luct 09 uct 06 luct 07 uct 06 duct 07	0 1/20 17 /20 /20 17 0 1/20 14 /0 1/20 17	tart Date	19 mm ASC;106	ting End Dat	
I I I I I I I I I I I I I I I I I I I	YE CA 10 in 1 BC 14 in 1 BC 20 in 1 BC 30 in 1 BC 40 in 1 BC	PSULE Package Descripti TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb	Size Imprint C on Dination Prod Dination Prod Dination Prod Dination Prod Dination Prod Dination Prod	Mluct09uct06luct07uct06luct07luct07	20 1/20 17 20 /20 17 0 1/20 14 /0 1/20 17 0 1/20 14	tart Date	19 mm ASC;106	ting End Dat	
Sile Sile <	YE CA 10 in 1 BC 14 in 1 BC 20 in 1 BC 30 in 1 BC 40 in 1 BC	PSULE Package Descripti TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb	Size Imprint C on Dination Prod Dination Prod Dination Prod Dination Prod Dination Prod Dination Prod	Mluct09uct06luct07uct06luct07luct07	20 1/20 17 20 /20 17 0 1/20 14 20 1/20 17 0 1/20 14 0 1/20 14 0 1/20 14	tart Date	19 mm ASC;106	ting End Dat	
Image: Section of the s	YE CA CA 10 in 1 BC 14 in 1 BC 20 in 1 BC 30 in 1 BC 40 in 1 BC 60 in 1 BC	PSULE Package Descripti TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb	Size Imprint C on Dination Prod Dination Prod Dination Prod Dination Prod Dination Prod Dination Prod	Mluct09uct06luct07uct06luct07luct07	20 1/20 17 20 /20 17 0 1/20 14 20 1/20 17 0 1/20 14 0 1/20 14 0 1/20 14	tart Date	19 mm ASC;106	ting End Dat	
I a log a	YE CA 10 in 1 BC 14 in 1 BC 20 in 1 BC 21 in 1 BC 30 in 1 BC 40 in 1 BC 60 in 1 BC	PSULE Package Descripti TTLE; Type 0: Not a Comb TTLE; Type 0: Not a Comb	Size Imprint C	M luct 09 uct 06 luct 07/ uct 06 luct 07/ duct 07/ duct 07/ duct 07/	20 1/20 17 20 /20 17 0 1/20 14 20 1/20 17 0 1/20 14 0 1/20 14 0 1/20 14		19 mm ASC;106	ting End Dat	

Labeler - Proficient Rx LP (079196022)

Establishment						
Name	Address	ID/FEI	Business Operations			
Proficient Rx LP		079196022	REPACK(63187-016, 63187-185), RELABEL(63187-016, 63187-185)			

Revised: 11/2019

Proficient Rx LP